On Jan. 05, Dunn Jeffrey W divested U.S. $1,153,776 in shares of SI-BONE Inc.. The COB, Pres, CEO sold 40,000 shares at a price per share of $28.84. The transaction decreased this specific insider’s holdings to 459,818 shares worth around $13.33 million at present.
Needham maintained its SI-BONE Inc. [SIBN] rating to the equivalent of a Buy but changed the price target to $35 from $28, in a research note dated December 16, 2020. That figure represents around a 17.14% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Needham’s analysts reiterating the shares to “a Buy” rating in a research note to investors issued in mid December. Meanwhile, Needham had maintained its rating on SIBN to the earlier “Buy” rating, in a research note produced for clients August 04, 2020.
Is SI-BONE Inc. [NASDAQ:SIBN] a Good Buy Right Now?
It should be noted that SIBN technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 100% Buy in the past month. Data from SI-BONE Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 0.39 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.29 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.27 million shares.
SIBN Price Performance
On Wall Street, SI-BONE Inc. [NASDAQ:SIBN] finished Thursday’s session up 0.55% at $29.00. The stock went up to $29.68 at the same session while its lowest single day price was $26.96. In the last five days, it saw a fall of about -1.46%, SI-BONE Inc. shares dropped by almost -3.01% since the beginning of the year. However, the share price has dropped to as low as -9.38% below its one year high. On 01/04/21, the company shares recorded $30.50, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/07/21, the same year at $26.96. The company’s shares have inclined by 35.32% in the past year. The 50-day SMA achieved is $25.08 while the 200-day SMA is $19.97. Volume gained to 0.52 million from 0.36 million in the previous session.
SIBN Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 27.41 level, and in case of violation of this particular level, it will cause more drop to 25.83 level. On the upper level, 31.27 is still the key resistance. The stock may increase to the subsequent resistance at 30.13. The Relative Strength Index (RSI) pinned on the 14-day chart is 58.71, implying a neutral technical stance while the MACD stands at -0.90, meaning price will decrease in the next trading period. Percent R indicator moved to 59.52%, implying low price movement. Stochastic %K at 38.37% suggest holding the stock.
What is the short interest in SI-BONE Inc.?
Short interest in the SI-BONE Inc. stock has plunged, decreasing by -0.13 million shares to total 0.52 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.4 million, data from Yahoo Finance shows. The increase of 24.1% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 1.79% of the overall float for the stock.
SI-BONE Inc.’s Biggest Shareholders: Who Owns SI-BONE Inc. [SIBN]?
Filings by Gilder, Gagnon, Howe & Co. LLC showed that the firm now holds a total of 1,985,250 shares or roughly 6.14% of the outstanding SIBN shares. This means their shares have increased by 640,043 from the 1,985,250 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, BlackRock Fund Advisors updated stake is worth $37,068,993. Details in the latest 13F filings reveal that OrbiMed Advisors LLC disposed off their -0.93% stake valued at $31,694,460 while Millennium Management LLC cut theirs at $26,860,227. During the last quarter, OrbiMed Advisors LLC liquidated -12,800 of its shares in SI-BONE Inc. while Millennium Management LLC sold -29,716 shares. The Driehaus Capital Management LLC’s holdings currently number 1,155,594 shares at $33512226.0. According to the firm’s last 13F report, The Vanguard Group, Inc. shares in the company at filing stood at 1,143,363 shares, roughly $26,480,287.
SIBN Earnings Forecast For The Current Quarter
SI-BONE Inc. [SIBN] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $22.15M and an earnings per share of -$0.3 for Dec 2020. Looking further ahead, the company is expected to report revenue of $20.93M at an EPS of -$0.35 for Mar 2021. The estimates represent upside of 29.30% and 11.80% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
SIBN Earnings Estimates For The Current Year
For the financial year, SI-BONE Inc. [NASDAQ:SIBN] is expected to bring in revenue of $73.4M. The returns are nearly $6.1 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.53, higher than that of FY19 by $0.02. Estimates put this year’s earnings growth at 1.30%, 11.80% for the next, and at an annual 21.10% over the next 5-year period. As for sales, forecasts are for an increase of 9.10% in the current fiscal year and a further 29.30% over the following year.
What are analyst thoughts on SI-BONE Inc.?
Looking forward to the SI-BONE Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for SI-BONE Inc. stock at $35.00 within the next 12 months, which represents almost 17.14 per cent growth from its previous closing price of $29.00. The highest analysts’ target for SI-BONE Inc. stock projections is $36.00 and the lowest one is $32.00. Still, 7 analysts sharing their consensus rating for SIBN stock in 2021 agree that it is a Buy.